A pharmacist working at a sterile compounding hood in a licensed pharmacy

HHS Peptide Policy: 6 Peptides Pharmacies Can Compound for Now


There is finally a federal lane for six popular peptides. In a notice filed Oct 28, 2026 and scheduled for the Federal Register on Oct 30, HHS says it “does not intend to take enforcement action” against state-licensed pharmacies, federal facilities or licensed physicians compounding BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. That is real progress on access. It is not FDA approval, and it says nothing about whether these peptides work.

Key facts

What did HHS actually change?

It changed who is likely to get in trouble, not what the FDA has approved. Enforcement discretion means an agency chooses not to act against something it could otherwise act on. HHS says the goal is “to expand and improve patient access” because of “significant interest” in these peptides and “the lack of availability of approved products.”

This is the document we were waiting on after the one-line White House filing on Oct 15. The list matches the July advisory vote, where the panel backed 6 of 7 peptides and rejected emideltide (DSIP).

Which forms are covered?

As summarized by AJMC and Drug Topics from the HHS appendix:

Peptide Form Routes covered
BPC-157 Acetate Under the skin, into muscle, oral, topical
TB-500 Acetate Under the skin or into muscle
MOTS-c Acetate Under the skin or into muscle
Epitalon Acetate Under the skin or into muscle, in intermittent courses
KPV Acetate Topical or oral
Semax Free base Intranasal

This table describes the policy’s scope. It is not guidance on how anyone should use these peptides. Drug Topics reports that IV use, injectable KPV and injectable Semax fall outside it. So do CJC-1295, ipamorelin, AOD-9604 and emideltide.

What do pharmacies have to do?

The conditions are the good part of this story, because they are built around the problems of the gray market:

HHS frames this as a controlled alternative to research-use products from foreign manufacturers, according to AJMC. The gap is real: one physician told AJMC that gray-market peptides often contain 5% to 75% of the labeled amount.

The honest caveats

Access and proof are different things.

Closer, not settled. As of Oct 30, 2026, BPC-157 is still unapproved and still not on the 503A Bulks List. What is new is that HHS says it does not intend to enforce against compounders who meet the conditions. The policy does not stretch to 503B outsourcing facilities, explained in our 503A vs 503B guide.

States are a separate layer. Jeff Cohen of the American Peptide Association told Reuters, as quoted by AJMC, that states may not follow the federal move. Louisiana went the other way with Act 374, effective Aug 1, 2026, which bars licensing boards from prohibiting compliant peptide prescribing and compounding. Check the current status of each peptide on our legal status tracker.

What comes next

What it means for you

If one of these peptides is on your radar, the legit path now looks like any other compounded prescription: a licensed provider evaluates you, decides whether it makes sense, and sends a patient-specific prescription to a licensed compounding pharmacy that can meet these conditions. Expect to pay cash, since AJMC notes compounded drugs generally sit outside standard pharmacy coverage. The policy offers no promise of results. Bring your questions to a licensed provider, and read how peptides get prescribed so you know what a real process looks like.

Sources

Educational content only, not medical advice or legal advice. Talk to a licensed provider about whether any medicine is right for you.

← All articles